Merck is funding the buyout of Verona Pharma, tapping into the U.S. bond market for a $6 billion transaction.
2 reports, 2 independent
Updated Sep 6
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Merck is funding the buyout of Verona Pharma, tapping into the U.S. bond market for a $6 billion transaction.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Merck acquired Verona's Ohtuvayre asset, which is subject to Phase III trials in China.Sub-event
Merck is acquiring Verona Pharma using a $6 billion raise in the U.S. bond market.1 source
Keep exploring
The entities involved
-
Merck
public company in Indonesia
-
Verona Pharma
company in London, United Kingdom
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- ReutersCompanies tap US bond market for nearly $70 billion, starting September on a busy note By Matt Tracy WASHINGTON (Reuters) -Investment-grade corporate borrowers tapped U.S. debt markets for nearly $70
- Insider MonkeyHere’s How Wall Street is Reacting to Verona Pharma (VRNA)’s Acquisition Verona Pharma plc (NASDAQ:VRNA) is one of the Best Mid Cap Growth Stocks to Buy According to Hedge Funds. On July 9, Verona Ph